| P/E (FY) | — | Sales (TTM) | $218.7M |
| Earnings (TTM) | -$140.1M | ROE | −10.92% |
| Net Margin | −51.99% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 62.54% |
IDEAYA Biosciences is a precision medicine oncology company developing targeted therapeutics for patient populations selected using molecular diagnostics in the United States. Its candidates include Darovasertib, an oral PKC inhibitor for uveal melanoma and ocular cancer evaluated as monotherapy and with crizotinib; IDE849, a DLL3 antibody drug conjugate; IDE034, a bispecific conjugate; IDE161, a PARG inhibitor; IDE705, a helicase inhibitor in Phase 1; and IDE397, a MAT2A inhibitor.
| Market Cap | $3.18B | Trading Days | 1799 |
| 52W High | 40.58 |
| 52W Low | 22.09 |
| % Off High | −10.89% |
| YTD | 4.60% | 1Y | 44.52% |
| 3Y | 66.94% | 5Y | 51.11% |
| Since incept. (ann.) | 17.74% |
| Ann. Volatility (1Y) | 48.26% | Ann. Volatility (3Y) | 49.40% |
| Sharpe (1Y) | 1.02 | Sharpe (3Y) | 0.61 |
| Max Drawdown (1Y) | −26.39% | Max Drawdown (3Y) | −69.23% |
| Beta (3Y, vs SPY) | 0.23 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | $3.27B | — |
| RCUS | Arcus Biosciences, Inc. | $3.40B | — |
| CUE | Cue Biopharma, Inc. | $2.87B | — |
| MBX | MBX Biosciences, Inc. | $2.86B | — |
| IRON | Disc Medicine, Inc. | $2.85B | — |
| OGN | Organon & Co. | $3.55B | 18.8 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.55B | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.77B | — |
| DYN | Dyne Therapeutics, Inc. | $3.70B | — |
| ATAI | AtaiBeckley Inc. | $2.64B | — |
| IMNM | Immunome Inc. | $2.63B | — |
| CPRX | CATALYST PHARMACEUTICALS, INC. | $3.85B | 18.7 |
